Eli Lilly and Novo Nordisk face a perceived obesity-treatment gap, with Rhythm Pharmaceuticals drawing investor interest

Eli Lilly and Novo Nordisk are widely seen as the backbones of today’s obesity drug boom, but a market-focused commentary published by Yahoo Finance says they “can’t treat this form of obesity” being discussed by investors. The piece frames the gap less as a demand problem and more as a clinical coverage problem, suggesting that not all obesity presentations respond to the same interventions that have powered growth for the two large pharma companies.

The article’s main equity hook is Rhythm Pharmaceuticals, a much smaller biotechnology company whose name has circulated in obesity-adjacent discussions. According to the Yahoo Finance note, billionaire investor Stanley Druckenmiller is betting that Rhythm Pharmaceuticals can address a form of obesity that existing leaders cannot, implying an unmet need that could translate into differentiated science and potential market share if clinical results bear out.

Beyond the framing that Lilly and Novo “can’t treat” the specific obesity type in question, the post’s approach is to connect investor positioning to an opportunity set. In other words, the commentary uses Druckenmiller’s interest as a announcement that the obesity pipeline may include targets and mechanisms outside the dominant playbook, even as large-cap players continue to expand prescription use and indications.

Rhythm Pharmaceuticals, in this context, is treated as the vehicle for that alternative mechanism. However, the material provided for this story does not include the underlying rationale, the biology it targets, or the clinical stage details that would normally accompany an investment thesis. As a result, readers do not get in this account a clear description of the specific obesity subtype, biomarkers, patient selection criteria, or trial endpoints that define “this form” of obesity.

Eli Lilly and Novo Nordisk are the central comparison points in the note, which implicitly contrasts current obesity treatment capabilities with what the commentary says remains untreated. The companies have not commented in the provided material on the specific claim about an obesity subtype, nor has the post offered public, primary-source details such as trial registry numbers, data cut dates, or disclosed results to substantiate the distinction.

It is also not clear from the available information whether the “can’t treat” language refers to lack of efficacy, absence of approved labeling, limited subgroup performance, or a mechanistic mismatch for a particular obesity driver. Those distinctions matter because they change what “gap” means to clinicians and payers, and they affect whether the opportunity is regulatory, competitive, or purely scientific.

For markets, the implication is that obesity treatment may remain a multi-track sector rather than a single winners-take-all story. If investors believe a smaller biotech can deliver outcomes for a narrower or different patient population, that could support funding, collaboration interest, and valuation for companies early in development, even while the biggest players consolidate broad usage.

What to watch next is whether Rhythm Pharmaceuticals provides clearer public updates tied to the obesity “form” described in the commentary, such as trial design disclosures, efficacy and safety indicates, or any regulatory milestones. Equally important, investors will look for independent confirmation that the limitation attributed to Lilly and Novo is well-defined and clinically meaningful, not just a rhetorical distinction in a market note.